#United States #Securities Fraud #Radnor #ImmunityBio #IBRX

Investors of ImmunityBio, Inc. Face Deadline in Securities Fraud Case

ImmunityBio, Inc. (NASDAQ: IBRX) is currently embroiled in a securities fraud class action lawsuit, and investors who purchased the company's securities between January 19, 2026, and March 24, 2026, may have to take action soon to protect their rights. The deadline for investors to file for lead plaintiff status in this case is May 26, 2026. This article aims to provide a comprehensive overview of the ongoing situation, including critical timelines and the implications for affected investors.

Case Overview

The lawsuit against ImmunityBio was filed in the U.S. District Court for the Central District of California. Named Douglas v. ImmunityBio, Inc., Case No. 226-cv-03261, the class action argues that the company made significant misstatements and omissions regarding its lead biologic product, Anktiva. Investors could face losses as a result of these alleged misrepresentations.

Allegations

The central claims of the lawsuit include:
1. False claims about Anktiva's capabilities: The lawsuit alleges that ImmunityBio's assertion that Anktiva acts as a cancer vaccine was misleading.
2. Misrepresentation by executives: The Executive Chairman, Patrick Soon-Shiong, supposedly overstated the drug's effectiveness, making claims that Anktiva could “cure and even prevent all cancer.”
3. Misleading information: These inaccuracies are said to have affected investor perceptions of the company's overall health, leading to misguided optimism regarding its business prospects.

Stock Price Impact

The repercussions of these claims became evident on March 24, 2026, when Bloomberg reported that the FDA issued a warning letter to ImmunityBio. The letter indicated that Soon-Shiong’s podcast remarks about Anktiva were considered false and misleading. Subsequently, ImmunityBio's stock plummeted by $1.98, representing a staggering 21.12% drop, closing at $7.42 per share.

What Affected Investors Can Do

Investors of ImmunityBio who believe they may have been impacted by these allegations must consider their legal options:

• - File for Lead Plaintiff Status: Investors have until May 26, 2026, to file for lead plaintiff status. A lead plaintiff acts on behalf of other investors and directs the litigation process.
• - Contact Legal Counsel: Affected investors are encouraged to connect with Kessler Topaz Meltzer Check, LLP, or other legal counsel, for a free case evaluation. It’s emphasized that there is no cost upfront, as representation typically works on a contingency fee basis.
• - Understand Your Rights: Potential plaintiffs should be aware that serving as a lead plaintiff might not affect their ability to recover damages.

Next Steps

The process for pursuing a claim involves potential class members selecting legal representation and filing necessary paperwork by the stated deadline. The legal firm, Kessler Topaz Meltzer Check, LLP, specializes in securities fraud and offers significant recoveries in similar class actions. The firm has recovered over $25 billion for its clients in historic litigations.

Why Timing is Critical

Legal proceedings of this nature can be complex and time-sensitive. Hence, it is strongly advised that those affected take prompt action. Investors might be seeking to navigate their legal rights and obligations in this unfolding situation.

Conclusion

As the May 26 deadline looms, ImmunityBio investors must assess their position carefully. With allegations pointing towards serious misleading information and substantial stock loss, proactive steps should be taken for those who believe they fall within the relevant time frame. Receiving accurate guidance from legal professionals will be paramount to understanding one’s rights and options.

For more information about the ongoing case, the community is encouraged to keep an eye on updates and legal advisories to make informed decisions moving forward.